稳定期急性心肌梗死PCI术后患者从替格瑞洛无引导降阶至氯吡格雷(TALOS-AMI):一项研究者发起的、开放标签、多中心、非劣效性随机试验
TALOS-AMI为开放标签、评估者盲法、多中心、非劣效性RCT,纳入韩国32家中心2697例AMI PCI术后1个月内无主要缺血或出血事件、正在服用阿司匹林+替格瑞洛的患者,1:1随机至降阶组(氯吡格雷+阿司匹林,无负荷量)或活性对照组(替格瑞洛+阿司匹林)。主要终点为1–12个月心血管死亡、心肌梗死、卒中或BARC 2/3/5型出血的复合终点。
要点
- 适用人群:AMI PCI术后1个月内无主要缺血或出血事件、正在服用阿司匹林+替格瑞洛的稳定患者;降阶为氯吡格雷+阿司匹林,不给予氯吡格雷负荷量。
- 降阶策略为非劣效且优效,净临床获益主要来自出血事件减少,缺血事件未增加。
适用人群与场景
- 韩国32家中心纳入的急性心肌梗死患者,接受阿司匹林+替格瑞洛,且指数PCI术后第一个月内无主要缺血或出血事件。
- 随机分组比例为1:1,降阶组接受氯吡格雷+阿司匹林,活性对照组接受替格瑞洛+阿司匹林。
诊断标准与关键阈值
- 主要终点为1至12个月内心血管死亡、心肌梗死、卒中或BARC 2、3、5型出血的复合终点。
- 出血定义采用Bleeding Academic Research Consortium(BARC)标准,包括2、3、5型。
处置流程与药物剂量
- 第一步:AMI PCI术后1个月内无主要缺血或出血事件、正在服用阿司匹林+替格瑞洛的稳定患者,可考虑降阶治疗。
- 第二步:从替格瑞洛转换为氯吡格雷时,采用无引导降阶策略,不给予氯吡格雷负荷剂量。
- 第三步:降阶组使用氯吡格雷+阿司匹林双联抗血小板治疗,对照组继续替格瑞洛+阿司匹林。
- 原文未提及氯吡格雷的具体剂量、给药途径、频次及疗程。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:研究者发起的、开放标签、评估者盲法、多中心、非劣效性随机试验(TALOS-AMI),共32家韩国中心,2697例患者随机(降阶组1349例,对照组1348例)。
- 原文未提及关键次要终点的其他具体结果及不良事件详细列表。
证据类型、等级与局限
- 证据类型:开放标签、评估者盲法、多中心、非劣效性随机对照试验(RCT)。
- 证据等级或推荐强度:原文未提及。
- 局限:开放标签设计;单国(韩国)多中心;随访至12个月;降阶策略为无引导转换;原文未提及其他局限。
对床旁实践的改变
- 对于AMI PCI术后1个月无主要缺血或出血事件的稳定患者,可考虑将替格瑞洛降阶为氯吡格雷(不给予负荷量)以降低出血风险,且不增加缺血事件。
- 降阶策略适用于稳定期患者,不适用于PCI术后1个月内发生主要缺血或出血事件的患者(原文排除条件)。
- 常见陷阱:降阶时不应给予氯吡格雷负荷剂量;本研究中降阶为无引导转换,未使用血小板功能检测指导。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients with acute myocardial infarction receiving potent antiplatelet therapy, the bleeding risk remains high during the maintenance phase. We sought data on a uniform unguided de-escalation strategy of dual antiplatelet therapy (DAPT) from ticagrelor to clopidogrel after acute myocardial infarction.
METHODS: In this open-label, assessor-masked, multicentre, non-inferiority, randomised trial (TALOS-AMI), patients at 32 institutes in South Korea with acute myocardial infarction receiving aspirin and ticagrelor without major ischaemic or bleeding events during the first month after index percutaneous coronary intervention (PCI) were randomly assigned in a 1:1 ratio to a de-escalation (clopidogrel plus aspirin) or active control (ticagrelor plus aspirin) group. Unguided de-escalation without a loading dose of clopidogrel was adopted when switching from ticagrelor to clopidogrel. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, or bleeding type 2, 3, or 5 according to Bleeding Academic Research Consortium (BARC) criteria from 1 to 12 months. A non-inferiority test was done to assess the safety and efficacy of de-escalation DAPT compared with standard treatment. The hazard ratio (HR) for de-escalation versus active control group in a stratified Cox proportional hazards model was assessed for non-inferiority by means of an HR margin of 1·34, which equates to an absolute difference of 3·0% in the intention-to-treat population and, if significant, a superiority test was done subsequently. To ensure statistical robustness, additional analyses were also done in the per-protocol population. This trial is registered at ClinicalTrials.gov, NCT02018055.
FINDINGS: From Feb 26, 2014, to Dec 31, 2018, from 2901 patients screened, 2697 patients were randomly assigned: 1349 patients to de-escalation and 1348 to active control groups. At 12 months, the primary endpoints occurred in 59 (4·6%) in the de-escalation group and 104 (8·2%) patients in the active control group (pnon-inferiority<0·001; HR 0·55 [95% CI 0·40-0·76], psuperiority=0·0001). There was no significant difference in composite of cardiovascular death, myocardial infarction, or stroke between de-escalation (2·1%) and the active control group (3·1%; HR 0·69; 95% CI 0·42-1·14, p=0·15). Composite of BARC 2, 3, or 5 bleeding occurred less frequently in the de-escalation group (3·0% vs 5·6%, HR 0·52; 95% CI 0·35-0·77, p=0·0012).
INTERPRETATION: In stabilised patients with acute myocardial infarction after index PCI, a uniform unguided de-escalation strategy significantly reduced the risk of net clinical events up to 12 months, mainly by reducing the bleeding events.
FUNDING: ChongKunDang Pharm, Medtronic, Abbott, and Boston Scientific.
参考来源
- Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021. PMID: 34627490. doi:10.1016/S0140-6736(21)01445-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。